Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Benefit of Endermology on Indurations and Panniculitis/Lipoatrophy During Relapsing-Remitting Multiple Sclerosis Long-Term Treatment with Glatiramer Acetate.
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.
GEMSP: A New Therapeutic Approach to Multiple Sclerosis.
Remyelination therapy goes to trial for multiple sclerosis
Disrupted balance of T cells under natalizumab treatment in multiple sclerosis.
The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod.
Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis.
Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series.
Immunomodulatory drugs (natalizumab), worsening of multiple sclerosis, rebound effect and similitude.
Role of the Blood-Brain Barrier in Multiple Sclerosis.
Differential effects of fingolimod on B-cell populations in multiple sclerosis.
The mystery of missing heritability: Genetic interactions create phantom heritability.
Laquinimod Phase IIa Study in Active Crohn's Disease
Monoclonal antibodies conjugated with superparamagnetic iron oxide particles allow magnetic resonance imaging detection of lymphocytes in the mouse brain.
4-aminopyridine toxicity: a case report and review of the literature.
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.
Increase in mRNA Level of Orexin1 and 2 Receptors Following Induction of Experimental Autoimmune Encephalomyelitis in Mice.
BTG Commences Phase IIa Study of Multiple Sclerosis
Gas6 increases myelination by oligodendrocytes and its deficiency delays recovery following cuprizone-induced demyelination.
Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
Copolymer 1 inhibits manifestations of graft rejection.
The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.
Epidemiology of Neuromyelitis Optica in the United States: A Multicenter AnalysisEpidemiology of NMO.
[Intractable vomiting as first manifestation of neuromyelitis Optica.]

Pages